The company, now based in North Beach, has lost more than $2 billion over 29 years. Its only approved drug, called roxadustat ...

AstraZeneca will buy longtime partner FibroGen's China unit for about $160 million to gain rights to its anemia drug in the ...

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be ...

FibroGen (NASDAQ:FGEN – Get Free Report) and Roche (OTCMKTS:RHHBY – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the ...

H.C. Wainwright analyst Matthew Keller keeps a Buy rating on FibroGen (FGEN) with a $10 price target after the company announced the sale of ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

FibroGen (NASDAQ:FGEN – Get Free Report) is anticipated to post its earnings results before the market opens on Monday, February 24th. Analysts expect FibroGen to post earnings of ($0.14 ...

The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through ...

AstraZeneca has agreed to acquire FibroGen’s China subsidiary for approximately $160m, securing full control over the anaemia drug roxadustat in the country. The deal strengthens AstraZeneca’s ...

Fibrogen said the deal will give AstraZeneca full rights to its anemia drug roxadustat in China. In December, AstraZeneca, which got about 12% of its 2024 sales from China, said it would buy ...

Feb 20 (Reuters) - AstraZeneca (AZN.L), opens new tab will buy longtime partner FibroGen's (FGEN.O), opens new tab China unit for about $160 million to gain rights to its anemia drug in the ...